EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies

Kausik K Ray, Helle Linnebjerg, Laura F Michael, Xi Shen, Xiaosu Ma, Shufen Lim, Eugene Y Zhen, Henryk Dudek, Marc Abrams, Utsav Saxena, Anton Turanov, Stephen J Nicholls und 1 weitere

Journal of the American College of Cardiology · 2025-05 · 85 (19) · 1803-1818

DOI: 10.1016/j.jacc.2025.03.005 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of the American College of Cardiology, 2025-05. Verfasst von Kausik K Ray und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Primary Care, Imperial College London, London, United Kingdom. Electronic address: k.ray@imperial.ac.uk. Hauptthemen laut MEDLINE: Angiopoietin-like Proteins, Dyslipidemias, RNA, Small Interfering. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly Indonesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The residual cardiovascular risk associated with hypertriglyceridemia and remnant particles supports efforts to develop effective novel therapeutic approaches. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases, and Mendelian randomization studies associate lower ANGPTL3 activity with lower triglycerides, and lower cardiovascular risk. OBJECTIVES: The aim of this study was to evaluate the impact of solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA developed to inhibit hepatic translation of ANGPTL3 messenger RNA (mRNA), on ANGPTL3 and lipid levels in preclinical models and humans. METHODS: In preclinical studies, the impact of solbinsiran on ANGPTL3 levels was assessed in mouse and nonhuman primate models. The phase 1 clinical study enrolled participants with mixed dyslipidemia. In the single-ascending-dose study, participants received single subcutaneous doses of solbinsiran (24-960 mg) or matching placebo. In the repeat-dose study, subcutaneous solbinsiran (208 or 480 mg) or matching placebo on days 1 and 29 was evaluated. Safety, pharmacokinetics, and effect on levels of ANGPTL3 and lipid parameters were evaluated over 169 days. RESULTS: In mice transiently expressing human ANGPTL3, a single dose of solbinsiran reduced hepatocyte ANGPTL3 mRNA expression by 65% vs vehicle-treated mice. In cynomolgus monkeys, mean ± SEM reductions in hepatic ANGPTL3 mRNA expression up to 73% ± 2% (P < 0.0001) and serum ANGPTL3 protein expression up to 69% ± 4% (P < 0.001) were seen vs vehicle-treated monkeys. In humans, a single dose of solbinsiran resulted in dose-dependent mean percentage reductions from baseline in ANGPTL3 up to 86% ± 4%, triglycerides up to 73% ± 7%, low-density lipoprotein (LDL) cholesterol up to 30% ± 16%, non-high-density lipoprotein cholesterol up to 41% ± 12%, and apolipoprotein B up to 30% ± 11%, with sustained effects at higher doses (P < 0.0001 for all). The repeat-dose study demonstrated reductions in ANGPTL3 of 89% ± 6%, triglycerides up to 70% ± 13%, LDL cholesterol up to 42% ± 14%, non-high-density lipoprotein cholesterol up to 46% ± 14%, and apolipoprotein B up to 36% ± 13% (P < 0.0001 for all). Nuclear magnetic resonance lipoprotein analysis demonstrated reductions in the total number of triglyceride-rich lipoprotein and LDL particles with solbinsiran. Adverse events were mostly mild in severity, with similar incidence in solbinsiran- and placebo-treated participants. CONCLUSIONS: Solbinsiran inhibits hepatic ANGPTL3 translation and results in significant reductions in all atherogenic lipoproteins in mixed dyslipidemia. The impact of this approach on cardiovascular outcomes remains to be determined. (A Study of LY3561774 in Participants With Dyslipidemia; NCT04644809).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-like ProteinsDyslipidemiasRNA, Small InterferingAdultAnimalsFemaleHumansMaleMiceMiddle AgedAngiopoietin-Like Protein 3Dose-Response Relationship, DrugMacaca fascicularisMice, Inbred C57BLOligonucleotides

Stichwörter der Autor:innen

ANGPTL3LDL-Cdyslipidemiasolbinsirantriglycerides

Substanzen

Angiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAngptl3 protein, mouseISIS 304801RNA, Small InterferingOligonucleotides

Autor:innen und Institutionen

  • Department of Public Health and Primary Care, Imperial College London, London, United Kingdom. Electronic address: k.ray@imperial.ac.uk.
  • Eli Lilly & Company, Indianapolis, Indiana, USA.
  • Dicerna Pharmaceuticals, Lexington, Massachusetts, USA.
  • Dicerna Pharmaceuticals, Lexington, Massachusetts, USA; Carbon Biosciences, Waltham, Massachusetts, USA.
  • Victorian Heart Institute, Monash University, Clayton, Victoria, Australia.
  • Eli Lilly & Company, Indianapolis, Indiana, USA. Electronic address: ruotolo_giacomo@lilly.com.

Förderung

  • Eli Lilly Indonesia

Zitieren

APA

Ray, K. K., Linnebjerg, H., Michael, L. F., Shen, X., Ma, X., Lim, S., Zhen, E. Y., Dudek, H., Abrams, M., Saxena, U., Turanov, A., Nicholls, S. J., & Ruotolo, G. (2025). Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. Journal of the American College of Cardiology, 85(19), 1803-1818. https://doi.org/10.1016/j.jacc.2025.03.005

Vancouver

Ray KK, Linnebjerg H, Michael LF, Shen X, Ma X, Lim S, et al. Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. Journal of the American College of Cardiology. 2025;85(19):1803-1818. doi:10.1016/j.jacc.2025.03.005

BibTeX
@article{Ray2025,
  author = {Ray, Kausik K and Linnebjerg, Helle and Michael, Laura F and Shen, Xi and Ma, Xiaosu and Lim, Shufen and Zhen, Eugene Y and Dudek, Henryk and Abrams, Marc and Saxena, Utsav and Turanov, Anton and Nicholls, Stephen J and Ruotolo, Giacomo},
  title = {Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies},
  journal = {Journal of the American College of Cardiology},
  year = {2025},
  volume = {85},
  number = {19},
  pages = {1803--1818},
  doi = {10.1016/j.jacc.2025.03.005}
}
Kostenlos starten →